How do you approach treatment of HR negative HER2+ metastatic breast cancer after WBRT for isolated CNS recurrence with continued systemic CR with first line TCHP?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?

How are you deciding between T-DXd/pertuzumab and THP> HP/tucatinib in patients with metastatic HER2+ breast cancer?

When using T-DXd/pertuzumab regimen in frontline treatment of HER2+ metastatic breast cancer, are you adapting the regimen with induction and then de-escalation to maintenance?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.